Cipla Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/j417yvu4nfdhcn9yla5uhesl.pdf

Key Takeaways


India Business: Recovery and the Obesity Bet

Achin Gupta: "This is tirzepatide is the first and only dual agonist of GIP and GLP-1, which makes it a very unique proposition. And while both products have been launched by the respective innovators, you can see from the uptake that the tirzepatide uptake is far ahead."

North America: Pipeline Building Against the Revlimid Decline

Umang Vohra: "Respiratory remains a cornerstone of our portfolio where we continue to invest with conviction."

International Markets: EMEU Shines, Africa Steady


Margins: Revlimid Exit and R&D Investment Reshape the Profile

Ashish Adukia: "In the first half of the year, you had the benefit of Revlimid also sitting out there, which will not be there in the second half. So that is one reason for the first half being at 25-plus-percent and second half being based on the margin guidance that we have given."

Leadership Transition and Strategic Continuity

Umang Vohra: "Cipla is an institution in and off by itself. So there will be continuity in what we are doing in terms of purpose, in terms of providing access in the leadership on respiratory therapy, in various segments that we've been building over the years."

Pipeline and Regulatory Milestones


Guidance & Commitments

CommitmentSpecificsTimeline
India business growthAt or higher than India market growth rateQ3 FY26
Full-year EBITDA margin22.75% to 24% (revised from 23.5%–24.5%), excluding YurpeakFY26
U.S. respiratory launchesFour major assets including generic AdvairCalendar year 2026
U.S. peptide launchesThree assets including liraglutideCalendar year 2026
Lanreotide market shareReach 30% or even 35%No date; capacity-driven
U.S. $1 bn sales run rateAchieve on a run-rate basisDuring next year
R&D spend overrunAbout 0.5% of revenue higher than plannedFY26
Indore facility reinspectionReinspection expectedAnytime this year and early next

Key Metrics

MetricQ2 FY26
Revenue₹7,589 cr, +8% YoY, highest ever quarterly revenue
EBITDA margin (excl. other income)25%
Gross margin after material cost67%, sequential decline of 160–170 bps due to product mix, R&D material purchases, and Africa tender business
Profit after tax₹1,351 cr, 17.8% of sales
Effective tax rate27%
R&D investment₹539 cr, 7.1% of revenue; full-year R&D now expected ~0.5% of revenue above original plan
Total expenses₹3,197 cr, +11% YoY, driven by R&D investments including litigation costs and elevated marketing spend
Net cash balance₹9,901 cr, after adjusting for over ₹400 cr dividend payout; debt including lease liability at ₹467 cr
Full-year EBITDA margin guidance22.75% to 24%, revised from 23.5% to 24.5%; excludes Yurpeak business plan
One-India revenue growth+7% YoY
North America revenue$233 million
U.S. albuterol MDI market share22%, Cipla emerged as number one player (IQVIA week ending Sep 19, 2025)
Lanreotide market share22% (MAT Aug '25)
EMEU revenue$110 million, strongest quarterly revenue till date, +15% YoY in USD terms
One Africa revenue growth+5% YoY in USD terms; South Africa +6% in ZAR terms
Chronic mix61.8% of branded prescriptions, strengthened YoY
Brands in INR 100 cr+ club29, 4 new brands added
Cipla unit sales in IPM200 cr+, only player at this volume level (IQVIA MAT Sep '25)
Chronic therapies CAGR16.4% from MAT Sep '21 to MAT Sep '25, revenues almost doubling
South Africa private market secondary growth6.2%, outperforming market growth of 4.7%
Generic Revlimid contributionVirtually nil to very marginal expected in Q3 FY26; Q2 contribution lower than prior year but not much lower
U.S. revenue directional target$1 billion next year, dependent on approval timing and launch cadence